Shanghai Clinical Center for Endocrine and Metabolic Diseases, Shanghai Institute of Endocrinology and Metabolism, Endocrine and Metabolic E-Institutes of Shanghai Universities-EISU, Shanghai, China.
PLoS One. 2012;7(11):e48777. doi: 10.1371/journal.pone.0048777. Epub 2012 Nov 7.
Liver fatty acid-binding protein (FABP1) plays an inconclusive role in adiposity. We investigated the association of serum FABP1 levels with obesity and insulin resistance in Chinese young people under 30 years old.
Cross-sectional analysis including 200 obese and 172 normal-weight subjects matched for age and sex, anthropometric measurements were performed and serum FABP1 and biochemical characteristics were measured. Insulin resistance was determined by homeostasis model assessment of insulin resistance (HOMA-IR) and by the insulin sensitivity index (S(i)) derived from Bergman's minimal model. FABP1 levels in obese subjects were significantly higher than those in normal-weight subjects (p<0.001) and the significance remained after adjustment for age, gender, alanine and aspartate aminotransferases (p<0.001). Serum FABP1 levels were significantly correlated with many metabolic-related parameters, with BMI and triglycerides as the independent determinants. FABP1 levels remained an independent risk factor of insulin resistance assessed by binary S(i) (OR = 1.868 per SD unit, 95% CI [1.035-3.373], p = 0.038) after adjustment for age, sex, BMI, waist circumference, systolic blood pressure, serum triacylglycerol, total cholesterol, HDL- and LDL-cholesterol,. FABP1 levels were also elevated with an increasing number of components of the metabolic syndrome (p for trend <0.001). Multiple regression modeling for the MetS and its components demonstrated that hypertriglyceridemia and low HDL-cholesterol were significantly correlated to serum FABP1 levels.
Serum FABP1 correlates positively with obesity and insulin resistance in Chinese young adults. Our data supports the fact that FABP1 might be an important mediator participating in fatty acid metabolism and energy balance.
肝型脂肪酸结合蛋白(FABP1)在肥胖中的作用尚无定论。我们研究了血清 FABP1 水平与中国 30 岁以下年轻人肥胖和胰岛素抵抗的关系。
纳入 200 名肥胖者和 172 名体重匹配的正常体重者进行横断面分析,测量人体测量学指标和血清 FABP1 及生化特征。采用稳态模型评估胰岛素抵抗(HOMA-IR)和 Bergman 最小模型衍生的胰岛素敏感指数(S(i))评估胰岛素抵抗。肥胖者血清 FABP1 水平显著高于正常体重者(p<0.001),且在调整年龄、性别、丙氨酸和天冬氨酸转氨酶后仍有显著差异(p<0.001)。血清 FABP1 水平与许多代谢相关参数显著相关,BMI 和甘油三酯是独立决定因素。在调整年龄、性别、BMI、腰围、收缩压、血清三酰甘油、总胆固醇、HDL-和 LDL-胆固醇后,FABP1 水平仍为二元 S(i)评估的胰岛素抵抗的独立危险因素(OR = 1.868/SD 单位,95%CI [1.035-3.373],p = 0.038)。随着代谢综合征及其各组分数量的增加,FABP1 水平也升高(趋势 p<0.001)。代谢综合征及其各组分的多元回归模型表明,高甘油三酯血症和低 HDL-胆固醇与血清 FABP1 水平显著相关。
血清 FABP1 与中国年轻成年人肥胖和胰岛素抵抗呈正相关。我们的数据支持 FABP1 可能是参与脂肪酸代谢和能量平衡的重要介质的事实。